• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Prostate Cancer Free for 10 Years, Stephen Karalekas Thanks OncBioMune for ProscaVax in Testimonial Video

    Matthew Spizziri
    Sep. 21, 2016 10:15AM PST
    Pharmaceutical Investing
    Company News

    OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces the release of a patient testimonial video by prostate cancer survivor Stephen Karalekas.

    OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces the release of a patient testimonial video by prostate cancer survivor Stephen Karalekas. The video tells the story of Mr. Karalekas and his experience with the OncBioMune team and the Company’s experimental immunotherapy prostate cancer vaccine, ProscaVax.
    Mr. Karalekas earned degrees at the United States Naval Academy, Harvard University and Indiana University before serving on the White House staff of President Richard Nixon and Capitol Hill as Chief of Staff for a Congressman from Massachusetts. Following that, he spent the rest of his time in Washington, D.C. as an attorney and lobbyist.
    Diagnosed with prostate cancer in March 2005, Mr. Karalekas underwent a radical prostatectomy and then, through a friend in Washington, D.C., was introduced to OncBioMune and ProscaVax. He subsequently began ProscaVax therapy in 2006. In the words of Mr. Karalekas, “low and behold, about six months later, my PSA had disappeared.” PSA is an acronym for “prostate specific antigen,” a commonly used measure of prostate cancer. Mr. Karalekas goes on to say that when the results of his PSA tests were obtained at the National Cancer Institute, the doctors were shocked, as they expected to see the progression of his disease marked by a continuing rise in his PSA.
    To this day, Mr. Karalekas still receives a ProscaVax booster shot every six months.
    “I am happy to say that 11 years later, I’m sitting before you in excellent health, no side effects, no issues, no problems and I’m in perfect health,” says Mr. Karalekas. “The doctors at the National Cancer Institute and, subsequently, at Mass General in Boston…say that there is nothing to be done, you’ll live a happy, normal, healthy existence.”
    “I would not like to finish this interview without expressing my profound gratitude and appreciation for OncBioMune, Dr. Jonathan Head and Dr. Robert Elliott for the work that they’re doing for mankind and the work that they did for me,” concluded Mr. Karalekas.
    The video is available for viewing at: https://vimeo.com/183563997
    Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.

    united statesprostate cancer
    The Conversation (0)

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×